Status:
COMPLETED
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Lead Sponsor:
Prometheus Laboratories
Conditions:
Metastatic Renal Cell Carcinoma
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.
Detailed Description
The PROCLAIM Registry is a US-based, multicenter Registry designed to establish a high quality observational database of real-world clinical data on HD IL-2 when used to treat patients with mRCC, mM o...
Eligibility Criteria
Inclusion
- 18 years or older
- Must have received at least one course of high dose IL-2 or Proleukin
- Signed informed consent form
Exclusion
- Prior high dose IL-2 or Proleukin therapy
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
1690 Patients enrolled
Trial Details
Trial ID
NCT01415167
Start Date
August 1 2011
End Date
May 1 2018
Last Update
June 13 2019
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Arizona Cancer Center
Tucson, Arizona, United States, 85742
2
Moores UCSD Cancer Center
La Jolla, California, United States, 92093
3
USC Norris Cancer Center
Los Angeles, California, United States, 90089
4
Southern California Permanente Medical Group
Riverside, California, United States, 92505